The Separation of Food and Drugs: HHS Under RFK
By Jason Meyers Cancer killed my mother and her 6 brothers and sisters. As an investment banker, I took many companies public including Alexion Pharmaceuticals and Medarex, Inc., as lead
By Jason Meyers Cancer killed my mother and her 6 brothers and sisters. As an investment banker, I took many companies public including Alexion Pharmaceuticals and Medarex, Inc., as lead
By Jason Meyers President-elect Donald Trump announced the appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services (HHS) on Thursday, marking a significant shift in the
Many of Trump's cabinet picks have raised concerns that the President-Elect is once again surrounding himself with tools of the State rather than leaders who will shake things up. But…
By Jason Meyers November 12, 2024 In a surprising move aimed at radically transforming government operations, it was reported that the Trump administration has announced that Elon Musk and Vivek
In the wake of the recent U.S. elections, Wyoming Senator Cynthia Lummis is making bold moves to position the nation as a leader in cryptocurrency. With plans to establish a…
Pacioli.ai is paving the way for a new approach to regulatory disclosure compliance and validation through its Initial Node Offering (INO). By blending decentralized finance with a robust compliance infrastructure,
By Jason Meyers Recently, Vice President-elect JD Vance hinted at a potential shift in U.S. support for NATO if Europe attempts to regulate Elon Musk’s social media platform, X. This
By Jason Meyers With the recent U.S. election signaling a shift in the regulatory landscape, the American Securities Association (ASA) has amplified calls for the immediate resignation of SEC Chairman
Edward Snowden’s comments at the Redacted conference touched on some of today’s most pressing issues: artificial intelligence, surveillance, and the blockchain ecosystem. His message was clear: decentralization is a vital…
In the rapidly evolving world of crypto, the U.S. has a rare opportunity under a potential second Trump administration to reshape regulatory practices and reduce budget allocations to zero, a